Table 2 Characteristics of retrospective controls and treated patients
From: Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Characteristic | Retrospective control group (N = 28) | Salovum group (N = 8) |
|---|---|---|
Age – yr (range) | ||
Median | 55.5 (50–62) | 57.5 (51–62) |
Gender – no. (%) | ||
Male | 18 (64) | 8 (100) |
Female | 10 (36) | 0 |
WHO/ECOG performance status – no. (%) | ||
0 | 18 (64) | 7 (88) |
1 | 6 (21) | 1 (13) |
2 | 3 (11) | 0 |
3 | 1 (4) | 0 |
Surgical resection – no. (%) | 28 (100) | 8 (100) |
GTR | 13 (46) | 3 (38) |
MGMT status – no. (%) | ||
Methylated | 4 (14) | 2 (25) |
Unmethylated | 6 (21) | 6 (75) |
Unknown | 18 (64) | 0 |
IDH status – no. (%) | ||
Wildtype | 19 (68) | 8 (100) |
Mutated | 0 | 0 |
Unknown | 9 (32) | 0 |
Survival time – no. (%) | ||
< 12 mo | 7 (25) | 1 (13) |
12–18 mo | 11 (39) | 2 (25) |
18–24 mo | 4 (14) | 1 (13) |
> 24 mo | 6 (21) | 4 (50) |
Median – mo (range) | 14.8 (3.4–60.6) | 23.0 (11.3–26.0) |
Time from diagnosis to recurrence – no. (%) | ||
< 6 mo | 8 (29) | 1 (13) |
6–12 mo | 13 (46) | 3 (38) |
≥ 12 mo | 6 (21) | 4 (50) |
Median – mo (range) | 9.4 (3.4–29.1) | 10.2 (4.3–26.0) |
Full radiotherapy completed – no. (%) | 27 (96) | 8 (100) |
Adjuvant TMZ cycles completed – no. (%) | ||
6 | 16 (57) | 4 (50) |
3–5 | 8 (29) | 3 (38) |
< 3 | 4 (14) | 1 (13) |
Second line treatment – no. (%) | ||
Lomustine | 12 (43) | 4 (50) |
TMZ | 4 (14) | 1 (13) |
None | 12 (43) | 3 (38) |